Mirati Therapeutics, Inc. (MRTX) financial statements (2022 and earlier)

Company profile

Business Address 3545 CRAY COURT
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,4911,39041522315157122
Cash and cash equivalents41388647331082249
Short-term investments1,078505369190433473
Receivables32     
Prepaid expense12861322
Other current assets  22211
Other undisclosed current assets2321000
Total current assets:1,5081,40442422715660125
Noncurrent Assets
Operating lease, right-of-use asset 40 
Property, plant and equipment16820111
Long-term investments and receivables816     
Long-term investments816     
Restricted cash and investments1      
Other noncurrent assets19961132
Other undisclosed noncurrent assets37      
Total noncurrent assets:817282143
TOTAL ASSETS:1,5891,47643222815763128
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:34714826141510
Accounts payable 18169462
Accrued liabilities9 2110665
Employee-related liabilities261486332
Other undisclosed accounts payable and accrued liabilities 3931000
Deferred revenue  1
Contract with customer, liability0
Other undisclosed current liabilities109      
Total current liabilities:144714926141510
Noncurrent Liabilities
Long-term debt and lease obligation4642     
Operating lease, liability4642 
Liabilities, other than long-term debt2211000
Accounts payable and accrued liabilities  11   
Other liabilities22  000
Total noncurrent liabilities:484411000
Total liabilities:1921155027141510
Stockholders' equity
Stockholders' equity attributable to parent1,3971,36138220214348118
Common stock0000000
Additional paid in capital3,1002,4811,145751594429415
Accumulated other comprehensive income91010991010
Accumulated deficit(1,712)(1,130)(772)(559)(461)(390)(307)
Total stockholders' equity:1,3971,36138220214348118
TOTAL LIABILITIES AND EQUITY:1,5891,47643222815763128

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues7213313   
Gross profit:7213313   
Operating expenses(645)(383)(225)(116)(72)(84)(65)
Operating loss:(573)(369)(222)(103)(72)(84)(65)
Nonoperating income (expense)(5)12126110
Investment income, nonoperating 1310  
Other nonoperating income (expense)(5)1194110
Loss from continuing operations before equity method investments, income taxes:(578)(357)(210)(97)(70)(83)(65)
Other undisclosed loss from continuing operations before income taxes (1)(3)(1)(0)  
Loss from continuing operations before income taxes:(578)(358)(213)(98)(70)(83)(65)
Income tax expense(3)      
Net loss available to common stockholders, diluted:(582)(358)(213)(98)(70)(83)(65)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(582)(358)(213)(98)(70)(83)(65)
Comprehensive loss:(582)(358)(213)(98)(70)(83)(65)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(0)0 (0)(0)0
Comprehensive loss, net of tax, attributable to parent:(582)(358)(213)(98)(70)(83)(65)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: